Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma

This study is testing the combination of two cancer drugs — tazemetostat (an epigenetic targeted drug) and venetoclax (which causes cancer cells to self-destruct) — in people with certain types of non-Hodgkin lymphoma that have returned or stopped responding to prior treatments. **You may be eligible if...** - You are 18 or older with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) - You have received at least two prior lines of therapy (for DLBCL) or at least two prior treatments (for FL) - You have at least one measurable tumor site of 1.5 cm or larger - Your blood counts and organ function meet required levels - You need treatment as determined by your doctor **You may NOT be eligible if...** - You have not tried prior standard treatments - Your blood counts, liver, or kidney function are too low - You have active serious infections or uncontrolled health conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.